Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
Clinical Infectious Diseases2008Vol. 47(10), pp. 1260–1269
Citations Over TimeTop 10% of 2008 papers
Chen‐Hua Liu, Chun‐Jen Liu, Chih‐Lin Lin, Cheng‐Chao Liang, Shih–Jer Hsu, Sheng‐Shun Yang, Ching‐Sheng Hsu, Tai‐Chung Tseng, Chia‐Chi Wang, Ming–Yang Lai, Jun‐Herng Chen, Pei‐Jer Chen, Ding‐Shinn Chen, Jia‐Horng Kao
Abstract
In treatment-naive Asian patients with HCV-1 infection, 48 weeks of pegylated IFN-alpha-2a plus ribavirin therapy is associated with a higher SVR rate, compared with 24 weeks of such therapy. Patients with a baseline serum HCV RNA level <800,000 IU/mL and who have achieved an RVR can receive a 24-week course of therapy without compromising the SVR rates; however, those who have not achieved an RVR but who have achieved a complete early virologic response should receive a 48-week course of therapy.
Related Papers
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2009)18 cited
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2005)5 cited
- → 576 Early detection of depressive symptoms during treatment with pegylated interferon α-2 and ribavirin in euthymic chronic hepatitis C patients(2006)
- → Dermatological Side Effects in a Patient with Hepatitis C Infection During Treatment with Pegylated Interferon/Ribavirin+Telaprevir: A Case Report(2014)
- → Pegylated Interferon, Ribavirin, and Sofosbuvir Combination versus Pegylated Interferon, Ribavirin in the Management of Chronic Hepatitis C Egyptian Patients(2017)